Brivaracetam (Brivaracetam)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Antiepileptic agents

Included in the formulation
  • Briviak
    pills inwards 
    YUSB Farma S.A.     Belgium
    • АТХ:

    N.03.A.X.23   Brivaracetam

    Pharmacodynamics:

    Due to selective inactivation of voltage-dependent sodium channels, it stabilizes neuronal envelopes in hyperexcitability zones.

    It binds the glycoprotein of synaptic vesicles 2A (SV2A) in the brain, which prevents the release of neurotransmitters during epileptic activity.

    Pharmacokinetics:

    After oral administration, it is completely absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is achieved after 0.5-4 hours. The connection with plasma proteins is 20%.

    Penetrates through the blood-brain and placental barrier. Metabolism in the liver to three inactive metabolites.

    The half-life is 7-8 hours. Elimination by the kidneys.

    Indications:

    It is used in the complex therapy of partial epileptic seizures in patients from 16 years of age and older.

    ICD-10

    VI.G40-G47.G40   Epilepsy

    Contraindications:

    Atrioventricular blockade of II-III degree, age to 16 years, pregnancy and lactation, individual intolerance.

    Carefully:

    Renal and hepatic insufficiency, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.It is used with caution, in cases where the expected effect exceeds the risk to the fetus and newborn.

    Dosing and Administration:

    Inside, 50 mg twice a day.

    The highest daily dose: 100 mg.

    The highest single dose: 50 mg.

    Side effects:

    Central and peripheral nervous system: dizziness, irritability, depression, drowsiness, cognitive impairment, movement coordination disorders, tremor, dysarthria, nystagmus, anxiety, suicidal thoughts.

    Respiratory system: upper respiratory tract infection, cough.

    Hemopoietic system: neutropenia.

    Digestive system: nausea, vomiting, decreased appetite, indigestion, dry mouth, weight loss.

    Musculoskeletal system: muscle spasms.

    Sense organs: diplopia, blurred vision, tinnitus.

    Allergic reactions.
    Overdose:

    Increased side effects.

    Treatment is symptomatic, hemodialysis.

    Interaction:

    Combines with all antiepileptic drugs.

    Simultaneous use of inducers of microsomal liver enzymes (carbamazepine, pregabalinum, lamotrigine) causes a decrease in the systemic concentration of brivaracetam.

    Rifampicin and St. John's wort (Hypericum perforatum) also cause a decrease in the concentration of Brivaracetam.

    Special instructions:

    Brivaracetam is often accompanied by dizziness, which can lead to falls and injuries. Patients should be careful.

    Persons caring for patients receiving brivaracetam, should be warned about the possibility of patients appearing suicidal thoughts and attempts.

    When taking the drug is not recommended driving and working with moving machinery.

    Instructions
    Up